Search

OSI-461

OSI-461 is a second-generation molecule belonging to a new class of drugs termed selective apoptotic anti-neoplastic drugs (SAANDs).

Elvucitabine

PI-166

It has demonstrated the ability to reduce the growth of rat hepatomas, which is like human hepatomas, are resistant to established anti-cancer agents. … PI-166 is a small organic compound with specific avidity to liver cancer cells.

Garenoxacin

Garenoxacin, a quinolone antibiotic, is being investigated for the treatment of gram-positive and gram-negative bacterial infections.

Ligelizumab

efficacy anti-IgE antibody therapy in the treatment of CSU has been previously established with omalizumab. … While the precise pathogenesis of CSU is not entirely clear, autoantibodies against IgE receptors, and sometimes against IgE itself, are thought to exist in 30-40% of patients,[A242362,A242367] and the

Rusalatide

TP508 is a non-proteolytic synthetic peptide representing the portion of human thrombin originally identified as the fibroblast high-affinity receptor binding domain.

Foretinib

Foretinib is an orally available small molecule compound designed to target multiple RTKs implicated in the development, progression and spread of cancer. … Foretinib has been used in trials studying the treatment of Cancer, Breast Cancer, Carcinoma, Renal Cell, Recurrent Breast Cancer, and Neoplasms, Head and Neck, among others.

MRx-4DP0004

MRx-4DP0004 is a lyophilised formulation of the Bifidobacterium breve strain of commensal bacteria. It is a live biotherapeutic derived from the microbiota of a healthy human infant.

Tesofensine

Veligrotug

[L63798] Thyroid eye disease has historically been managed differently depending on whether it is caught in the active inflammatory phase or has become chronic - Viridian describes veligrotug-vvze as the … [L63798] Although its precise mechanism in thyroid eye disease has not been fully characterized, IGF-1R blockade reduces the proptosis and diplopia that define the condition.